<DOC>
	<DOCNO>NCT02093923</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetic profile multiple subcutaneous administration DX-2930 across range dos Hereditary Angioedema subject .</brief_summary>
	<brief_title>Double-Blind , Multiple Ascending Dose Study Assess Safety , Tolerability Pharmacokinetics DX-2930 Hereditary Angioedema ( HAE ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>At least 18 year age time screen . Documented diagnosis HAE ( Type I II ) Experiencing â‰¥2 HAE attack per year , least 1 attack past 6 month report subject . Willing able read , understand , sign inform consent form . Females childbearing potential must agree abstinent else use acceptable form contraception throughout study Males female partner childbearing potential must agree abstinent use medically acceptable form contraception throughout study . Exposure investigational drug device within 90 day prior study . History exposure within past 5 year monoclonal antibody recombinant protein bear Fc domain . Concomitant diagnosis another form chronic angioedema Use longterm prophylaxis HAE within 90 day prior study . Use C1INH exceed total 30 day within past 90 day prior study ; use C1INH within 7 day prior study . Exposure angiotensinconverting enzyme ( ACE ) inhibitor estrogencontaining medication systemic absorption within 90 day prior study . Exposure androgens within 90 day prior study . Presence indwell catheter . Diagnosis HIV . Active liver disease liver function test abnormality History substance abuse dependence . Pregnancy breastfeed . Any condition , opinion Investigator , may compromise safety compliance , preclude successful conduct study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HAE</keyword>
</DOC>